Background-Treatments for non-ST-segment-elevation myocardial infarction (NSTEMI) reduce ischemic events but increase bleeding. Baseline prediction of bleeding risk can complement ischemic risk prediction for optimization of NSTEMI care; however, existing models are not well suited for this purpose. Methods and Results-We developed (nϭ71 277) and validated (nϭ17 857) a model that identifies 8 independent baseline predictors of in-hospital major bleeding among community-treated NSTEMI patients enrolled in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) Quality Improvement Initiative. Model performance was tested by c statistics in the derivation and validation cohorts and according to postadmission treatment (ie, invasive and antithrombotic therapy). The CRUSADE bleeding score (range 1 to 100 points) was created by assignment of weighted integers that corresponded to the coefficient of each variable. The rate of major bleeding increased by bleeding risk score quintiles: 3.1% for those at very low risk (score Յ20); 5.5% for those at low risk (score 21-30); 8.6% for those at moderate risk (score 31-40); 11.9% for those at high risk (score 41-50); and 19.5% for those at very high risk (score Ͼ50; P trend Ͻ0.001). The c statistics for the major bleeding model (derivationϭ0.72 and validationϭ0.71) and risk score (derivationϭ0.71 and validationϭ0.70) were similar. The c statistics for the model among treatment subgroups were as follows: Ն2 antithromboticsϭ0.72; Ͻ2 antithromboticsϭ0.73; invasive approachϭ0.73; conservative approachϭ0.68.
T reatment of non-ST-segment-elevation myocardial infarction (NSTEMI) traditionally has focused on prevention or minimization of ischemic complications with potent antithrombotic medications and catheter-based interventions. [1] [2] [3] Yet these reductions in recurrent ischemic events have come at the cost of increased major bleeding, 4 -7 which is itself associated with worse clinical outcomes. [7] [8] [9] [10] [11] [12] [13] Bleeding complications have received attention recently, in part because newer antithrombotic agents for NSTEMI have unique ischemia and bleeding profiles. Some agents demonstrate low rates of major bleeding with similar efficacy, 5, 14 whereas others demonstrate higher rates of major bleeding with superior efficacy. 15 Given the importance of safety and efficacy, 12 the recent American College of Cardiology/American Heart Association practice guidelines placed renewed emphasis on risk stratification to guide treatment for NSTEMI. 3 Although tools for ischemic risk stratification are well described (ie, TIMI [Thrombolysis In Myocardial Infarction], PURSUIT [Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using InTegrilin], and GRACE [Global Registry of Acute Coronary Events] risk scores), 16 -18 bleeding risk stratification is more limited. The few bleeding risk stratification models in existence include treatments known to influence bleeding or are derived from subgroups or trial populations not representative of those at greatest risk. 10, 13, 19 Consequently, better estimation of baseline risk of bleeding in NSTEMI patients is needed to facilitate optimal treatment selection.
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Using data from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) Quality Improvement Initiative, we developed and validated a scoring system to estimate baseline risk of in-hospital major bleeding in patients with NSTEMI. The CRUSADE bleeding score provides a tool that equips clinicians with the means to consider safety outcomes when making treatment decisions for patients with NSTEMI.
Methods
The CRUSADE Quality Improvement Initiative is a database of high-risk patients with non-ST-elevation acute coronary syndromes who were admitted to US hospitals from November 2001 through December 2006. 20 CRUSADE inclusion and exclusion criteria, data collection, and variables have been described previously. 21 Data on baseline and nadir hematocrit values were added to version 2 of the case report form, so the analysis in the present study was limited to patients enrolled from February 15, 2003 , through December 31, 2006 . The institutional review board of each center approved participation in CRUSADE. Because data were collected anonymously, informed consent was not required.
Population
The analysis population consisted of 89 134 patients enrolled across 485 US sites. Starting from the CRUSADE population that had recorded hematocrit values (nϭ118 252), patients with unstable angina (nϭ7173) and those taking warfarin at home (nϭ7752) were excluded owing to potential differences in treatment patterns that could influence bleeding risk. Patients transferred out of the CRU-SADE hospital (nϭ12 000) were also excluded, because treatments and outcomes after transfer could not be collected owing to current US privacy regulations. Patients with improperly recorded baseline hematocrit (nϭ739) or missing data on major bleeding (nϭ143) were excluded. Additionally, patients who died within 48 hours of hospital arrival (nϭ1311) were excluded because they represent a censored population that has a truncated opportunity for both treatment and major bleeding events. The study population was then divided by use of simple random sampling into a derivation cohort (80%, nϭ71 277) and a validation cohort (20%, nϭ17 857) for model development. Patients with missing variables for age, sex, and race were excluded from the model development process (derivation nϭ1545 and validation nϭ375).
Data Definitions
Baseline and nadir (lowest recorded) hematocrit were abstracted on the data collection form. Blood transfusion was defined as any nonautologous transfusion of whole or packed red blood cells. Witnessed bleeding was a variable on the case report form that required evidence of a bleeding location. CRUSADE major bleeding was defined as intracranial hemorrhage, documented retroperitoneal bleed, hematocrit drop Ն12% (baseline to nadir), any red blood cell transfusion when baseline hematocrit was Ն28%, or any red blood cell transfusion when baseline hematocrit was Ͻ28% with witnessed bleed. The hematocrit cut point of 28% was chosen to prevent transfusions given for baseline anemia from being considered as bleeding events. Because the primary goal of the present analysis was to identify baseline risk of bleeding, bleeding in patients who underwent coronary artery bypass graft (CABG) surgery was included in the analysis only if it occurred before surgery. Bleeding during or after surgery was not considered. Creatinine clearance was estimated with the Cockcroft-Gault equation. 22 Congestive heart failure was defined as signs of congestive heart failure at presentation, indicated by exertional dyspnea, orthopnea, shortness of breath, labored breathing, fatigue at either rest or with exertion, rales heard over more than one third of the lung fields, elevated jugular venous pressure, S 3 gallop, or pulmonary congestion on x-ray believed to represent cardiac dysfunction. Prior vascular disease was defined as either prior stroke or peripheral arterial disease.
Statistical Analysis
The relationship between potential covariates and major bleeding was explored using Wilcoxon rank-sum test for continuous and ordinal categorical variables and 2 test stratified by hospital for nominal categorical variables. Continuous variables (such as age, weight, baseline hematocrit, creatinine clearance, heart rate, and systolic blood pressure) were investigated for nonlinearity, and plots of each continuous variable versus rates of major bleeding were reviewed to create dichotomous cut points when suitable. Systolic blood pressure cut-point values of Ͻ110 mm Hg or Ͼ180 mm Hg were chosen because the relationship between bleeding and systolic blood pressure increased linearly past these ranges but was flat in between. Similarly, a cut-point hematocrit of 36% was chosen because major bleeding only increased below this value. In addition, heart rate values Յ70 bpm were set to 70 bpm and creatinine clearance values Ն120 mL/min were set to 120 mL/min because the relationship between heart rate and creatinine clearance with major bleeding was flat beyond those values.
Variables with clinically and statistically significant univariate relationships with major bleeding were included in the multivariate model. The degree of missing data was approximately 2% across covariates. Missing values were set to the lower-risk group for discrete variables and replaced with sex-specific medians for continuous variables. To investigate the sensitivity of missing data imputation, 2 sensitivity analyses were performed in which the first analysis excluded all missing data of the covariates in the model (eg, complete case analysis, nϭ63 117) and the second analysis imputed missing data of the discrete variables to the higher-risk group. Because the c statistics of the sensitivity analyses were not remarkably different from the main analysis in which missing values were set to the lower-risk group for discrete variables, only the main analysis is presented. The logistic generalized estimating equations method was used to account for within-hospital clustering. This method produces estimates similar to those obtained from ordinary logistic regression, but the estimated variances of the estimates are adjusted for the correlation of outcomes within a hospital. 23 The predictive performance of the model was assessed with c statistics and observed versus plots of predicted probabilities.
The CRUSADE bleeding score was developed by assigning a weighted integer to each independent predictor on the basis of its coefficient in the final model. A point score for each patient was calculated by summing the weighted integers (range 1 to 100 points). The predicted rate of major bleeding was plotted as a continuous function of the score. The bleeding score was also divided into quintiles: Very low risk (Յ20; nϭ19 486), low risk (21 to 30; nϭ12 545), moderate risk (31 to 40; 11 530), high risk (41 to 50; nϭ10 961), and very high risk (Ͼ50; nϭ15 210). The performance of the CRUSADE bleeding score was tested in derivation and validation cohorts, as well as in relevant postadmission treatment subgroups: Patients treated with Ն2 antithrombotic medications (antiplatelet [aspirin or clopidogrel], anticoagulant, or glycoprotein IIb/IIIa inhibitors; nϭ50 969); patients receiving Ͻ2 antithrombotic medications (nϭ5931); and, among patients receiving Ն2 antithrombotic medications, those who did not undergo cardiac catheterization (conservative strategy, nϭ3200) and those who underwent a cardiac catheterization (invasive strategy, nϭ43 492). In-hospital mortality was also determined for those who did and did not experience a major bleeding event in each risk group. In determining the association between in-hospital outcomes (major bleeding and mortality) and bleeding risk score groups, bleeding risk group was entered as an ordinal independent variable in the logistic generalized estimating equation models to test for a linear trend. All comparisons were 2-tailed, and P Ͻ0.05 was considered statistically significant. All analyses were performed with SAS software (version 9.1, SAS Institute, Cary, NC).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Baseline characteristics and outcomes of the derivation and validation cohorts were similar (Table 1) . CRUSADE patients had a median age of 67 years; 60% were male. A high prevalence of cardiovascular risk factors and of prior cardio-vascular disease was found. The rate of major bleeding was 9.4% in the derivation cohort and 9.6% in the validation cohort (PϭNS for cross-cohort comparisons). Among the patients with major bleeding, the (nonexclusive) occurrence of the individual components of the CRUSADE major bleeding definition were as follows: Intracranial hemorrhage, 0.7%; documented retroperitoneal bleed, 1.9%; hematocrit drop Ն12% (baseline to nadir), 44.4%; any red blood cell transfusion when baseline hematocrit was Ն28%, 68.6%; or any red blood cell transfusion when baseline hematocrit was Ͻ28% with witnessed bleed, 2.9%. Patients who experienced a CRUSADE major bleed (nϭ6701) had higher rates of in-hospital heart failure (15.9% versus 6.5%), cardiogenic shock (7.7% versus 1.5%), and mortality (8.5% versus 2.1%; all PϽ0.0001) than those who did not.
Univariate Associations With Major Bleeding
CRUSADE major bleeding was associated with older age (median 74 versus 67 years), lower weight (median 74.8 versus 81.6 kg), higher heart rate (median 90 versus 82 bpm), and lower systolic blood pressure (median 142 versus 144 mm Hg; all PϽ0.0001). Major bleeding was also significantly associated with lower baseline hematocrit and lower creatinine clearance (Table 2) . Tables 2 and 3 describe the  continuous (Table 2 ) and dichotomous (Table 3 ) risk factors used in the development of the bleeding model.
CRUSADE Bleeding Model and Risk Score
From multivariable analysis, the factors independently associated with major bleeding included baseline hematocrit, estimated creatinine clearance, baseline heart rate, baseline systolic blood pressure, female sex, signs of congestive heart failure on presentation, prior vascular disease, and diabetes mellitus ( Table 4 ). Although age was a univariate predictor, it did not remain an independent predictor of major bleeding after adjustment for other covariates. The final regression model (the CRUSADE major bleeding model) discriminated patients who did and did not have a major bleeding event in both the derivation (c statisticϭ0.72) and validation (c statisticϭ0.71) cohorts. The CRUSADE bleeding score ( Table 5 ) was derived by assigning weighted integers to each independent predictor on the basis of its coefficient in the regression model. The sum of the weighted integers (range 1 to 100 points) estimates the risk of in-hospital major bleeding. Figure 1 demonstrates the curvilinear relationship between CRUSADE bleeding score and predicted probabilities of major bleeding observed in the derivation cohort, in which the rate of bleeding increased 10-fold (Ͻ3% to Ͼ30%) from the lowest to the highest scores. Similar to the multivariable model, the CRUSADE bleeding score had good ability to discriminate between patients who did and did not have a major bleeding event in the derivation (c statisticϭ0.71) and validation (c statisticϭ0.70) cohorts. The CRUSADE bleeding model was similarly able to predict rates of moderate to severe bleeding according to the GUSTO [Global Utilization of Streptokinase and t-PA for Occluded coronary arteries) definition (c statisticϭ0.71; data not shown). Figure 2 compares the rates of in-hospital major bleeding across quintiles of risk according to CRUSADE bleeding score in the derivation and validation cohorts. In the derivation cohort, the rates of major in-hospital bleeding across the quintiles of risk groups were 3.1% (very low risk), 5.5% (low risk), 8.6% (moderate risk), 11.9% (high risk), and 19.5% (very high risk). The rate of major bleeding also increased across quintiles of risk groups in the validation cohort (P trend Ͻ0.001; Figure 2 ).
CRUSADE Bleeding Score in Treatment Subgroups
CRUSADE includes patients who underwent an initial invasive strategy with cardiac catheterization (nϭ52 048) and subsequent revascularization (nϭ38 209), as well as those managed medically (without catheterization, nϭ6407). Treatments (ie, invasive care or antithrombotics) that increase the risk of bleeding were intentionally omitted from the CRUSADE bleeding score; however, the performance of the CRUSADE bleeding score across treatment subgroups was confirmed by formal testing.
The model had preserved discrimination in groups of patients who received Ն2 antithrombotic medications and those who received Ͻ2 antithrombotic medications (c statis-tics 0.72 and 0.73, respectively). With the derivation cohort, the incidence of major bleeding was 8.2% among those who received Ն2 antithrombotic medications (nϭ50 969) versus 6.9% among those who received Ͻ2 antithrombotic medications (nϭ5931). The rate of major in-hospital bleeding was higher when Ն2 antithrombotic medications were given than when Ͻ2 antithrombotic medications were given in every risk quintile: 3.1% versus 1.9% (very low risk), 5.5% versus 2.6% (low risk), 8.4% versus 5.3% (moderate risk), 12.0% versus 6.7% (high risk), and 19.9% versus 13.5% (very high risk; P trend Ͻ0.001 within each of the 2 strata; Figure 3 ). However, the absolute difference in bleeding was greater in the high-risk and very-high-risk groups.
Among patients receiving Ն2 antithrombotic medications, the c statistic of the model in those treated with a conservative approach (no catheterization) was 0.68, whereas the c statistic of the model in those treated with an invasive approach (catheterization) was 0.73. The rate of major in-hospital bleeding was higher if patients underwent an invasive approach than if they were treated with a conservative approach in every risk quintile: 3.1% versus 2.5% (very low risk), 5.6% versus 3.2% (low risk), 8.6% versus 6.4% (moderate risk), 13.4% versus 6.4% (high risk), and 22.6% versus 13.9% (very high risk; Figure 4) . Similarly, the absolute difference in major bleeding was magnified in the high-risk and veryhigh-risk groups. In-hospital mortality rates increased along with the CRUSADE bleeding risk quintiles. The rate of in-hospital mortality is also shown for patients who did and did not have a bleeding event within each CRUSADE bleeding risk group; in each bleeding risk quintile, patients who experienced a major bleed had higher mortality than those who did not ( Figure 5 ).
Discussion
The CRUSADE bleeding score, which predicts baseline risk of in-hospital major bleeding, was developed and validated in Ͼ89 000 community-treated NSTEMI patients. It is unique in that it only considers admission variables, including baseline characteristics, clinical presentation, and key laboratory data. The 8 variables in the final model were female sex, history of diabetes, prior vascular disease, heart rate, systolic blood pressure, signs of congestive heart failure, baseline hematocrit Ͻ36%, and creatinine clearance. Although postadmission treatments were not included in the model, the CRUSADE bleeding score demonstrated preserved discrimination across treatment subgroups. Therefore, it complements ischemic risk prediction, enabling clinicians to consider net clinical outcomes in patients with NSTEMI.
Bleeding is a common problem that complicates treatment of NSTEMI, with important immediate and late clinical consequences. Clinical trials involving almost 48 000 patients with NSTEMI have demonstrated that major bleeding is associated with a 5-fold increase in 30-day mortality. 8, 9 Observations from a randomized trial comparing antithrombotic agents suggest that a reduction in bleeding events translates into improved survival. 14 Prevention of major bleeding may represent an achievable step in improving outcomes by balancing safety and efficacy in the treatment of NSTEMI. Several studies have examined predictors of major bleeding or developed predictive instruments for the estimation of bleeding risk in this population. 9, 10, 13, 19 Moscucci et al 10 determined independent predictors of bleeding among 24 045 STEMI and NSTEMI patients in the GRACE registry. Similar to the present results, they observed that female sex, renal insufficiency, and blood pressure were independent predictors of major bleeding. More recently, Spencer et al 13 also found that female sex, peripheral artery disease, heart rate, and renal insufficiency were among the predictors of major bleeding in the first 30 days after admission in GRACE. Only 1 other study has developed a risk stratification tool or bleeding score. Nikolsky et al 19 used 6002 patients enrolled in the REPLACE (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events)-2 trial to derive and 1056 patients enrolled in REPLACE-1 to validate a risk score to predict major bleeding for patients undergoing elective or urgent percutaneous coronary intervention via the femoral approach. Similar to the CRUSADE bleeding score, Nikolsky et al 19 found that female sex, baseline anemia, and lower creatinine clearance were independent predictors of bleeding. However, REPLACE-2 enrolled a highly selected population, all of whom underwent percutaneous coronary intervention by the femoral approach, which limits its generalizability. Furthermore, the predictive model from GRACE 10, 13 and the risk score from REPLACE-2 19 included treatment variables (eg, invasive procedures and antithrombotics), which limits their utility for assessing bleeding risk at presentation. These studies, therefore, do not address baseline risk in a community population.
The CRUSADE bleeding score builds on these studies in several ways. It was developed in a diversely treated community population that included those undergoing initial invasive strategy and revascularization and those conservatively managed without catheterization. It includes only baseline factors, including creatinine clearance, a more precise estimate of renal function than creatinine or a history of renal insufficiency. Age was a significant univariate predictor of bleeding; however, it did not remain significant in multivariable testing owing to other variables such as creatinine clearance that may account for age-associated risk. 24 -26 How- Rate of major bleeding across CRUSADE bleeding score risk groups in the derivation and validation cohorts. Very low (bleeding score Յ20): derivation nϭ19 486 and validation nϭ4920; low (bleeding score 21 to 30): derivation nϭ12 545 and validation nϭ3141; moderate (bleeding score 31 to 40): derivation nϭ11 530 and validation nϭ2873; high (bleeding score 41 to 50): derivation nϭ10 961 and validation nϭ2787; and very high (bleeding score Ͼ50): derivation nϭ15 210 and validation nϭ3761. P trend Ͻ0.001. ever, female sex, diabetes, and signs of congestive heart failure continue to contribute unique information on bleeding risk. Importantly, the CRUSADE bleeding score has preserved discrimination regardless of treatment (eg, antithrombotic medications or invasive care), which increases its utility in clinical decision making.
The effect of treatment strategy on the incidence of bleeding in the study population is evident (Figures 3 and 4) , because multiple antithrombotic agents or an invasive approach increased the risk of bleeding in every CRUSADE bleeding score quintile. Furthermore, the gradient of bleeding risk related to treatment appears magnified in the high and very high quintiles of the CRUSADE bleeding score. These findings imply that those at high risk may have reduced bleeding rates with careful treatment selection, although the effect of such adjustments in treatment strategy on outcomes will require confirmation by prospective testing.
The CRUSADE bleeding score identifies baseline factors associated with an increased propensity for bleeding. More-over, those who experience a bleeding event have higher in-hospital mortality across all quintiles of baseline risk. The mortality among those who experience a bleeding event is also higher within each quintile ( Figure 5 ). Identification of patients with a higher propensity for bleeding can lead to improvements in NSTEMI care by prompting clinicians to make judicious treatment selections, carefully dose antithrombotic medications, and select invasive strategies to optimize patient-centered care. 27, 28 With a growing number of antithrombotic agents available, 5, 14, 15, 29, 30 appreciation of baseline bleeding provides an objective starting point either for treatment selection or for strategy comparison. The CRUSADE bleeding score provides a complement to existing risk stratification.
Study Limitations
Several limitations of the present analysis should be considered. Given the dependence on registry data for this analysis, we chose to limit our population to those with NSTEMI, to . Rate of major bleeding among patients treated with Ն2 antithrombotic drugs undergoing an invasive approach (catheterization) vs a conservative approach (no catheterization) across CRUSADE bleeding score in the derivation cohort. Quintiles were defined as follows: Very low (Յ20), nϭ16 974; low (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , nϭ10 067; moderate (31-40), nϭ8142; high (41-50), nϭ6105; and very high (Ͼ50), nϭ5404. P trend Ͻ0.001 within each of the 2 strata. limit the number of false-positives. When unstable angina patients were included (nϭ5462), the model c statistic did not change (c statisticϭ0.72). We conclude our model will predict bleeding events in the high-risk acute coronary syndrome population. Another possible limitation could be that some initial bleeding events were not included, because patients who died within 48 hours of hospitalization were excluded from the analysis; however, a validation analysis that included early deaths (nϭ1311) did not alter the c statistic of the model (c statisticϭ0.71). The rate of major bleeding is higher in CRUSADE than in other studies because of the complex patient population or the definition of major bleeding. The definition of in-hospital major bleeding used in the present study has been published previously 31 and is an adaptation of existing major bleeding definitions as applicable to the CRUSADE data collection methods. 5, 32, 33 CRUSADE collected only hematocrit levels (not hemoglobin). In addition, a history of prior bleeding or bleeding diathesis, both of which are recognized predictors of in-hospital bleeding, 13 was not collected in CRUSADE. Patients taking warfarin at admission were excluded, so additive risk was not considered. Finally, the c statistic of the CRUSADE in-hospital major bleeding model at 0.72 in the derivation cohort and 0.71 in the validation cohort is modest but nevertheless better than that of other bleeding models. 10, 19 
Conclusions
The CRUSADE bleeding score combines 8 baseline factors that predict the propensity for major bleeding into a simple validated tool to assist with risk assessment and optimize care of patients with NSTEMI.
An automated Web tool for calculation of the CRUSADE Bleeding Score is available at http://www.crusadebleedingscore. org.
Sources of Funding
The CRUSADE Registry is funded by Millennium Pharmaceuticals and Schering-Plough Corporation. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides an unrestricted grant in support of the program. This work was also supported in part by a grant from the National Institute on Aging (R01 AG025312-01A1; Dr Peterson, Principal Investigator) and the American Heart Association. Investigators had full direct access to the data and performed the actual analysis. None of the sponsors played a role in conducting the analysis or in interpreting or reporting the results.
Disclosures
Dr Bach receives research support from AstraZeneca, Schering-Plough Research Institute, Eli Lilly/Daiichi-Sankyo, and The Medicines Company and is a speaker for Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Dr Rao serves as a speaker and clinical investigator for Johnson & Johnson and as a consultant for sanofiaventis and The Medicines Company; he is also a principal investigator for Momenta Pharmaceuticals. Dr Newby serves as a consultant for Astra Zeneca, Atherogenics, Biosite, CV Therapeutics, Novartis, Proctor & Gamble, and Roche Diagnostics; as principal investigator or coinvestigator for BG Medicine, Medicure, and Schering-Plough; as an expert reviewer for Adolor; as a Clinical Event Committee reviewer for Inverness Medical; and as a board member for the Society of Chest Pain Centers. Dr Wang is a principal investigator for Bristol-Myers Squibb, sanofi-aventis, and Schering-Plough. Dr Gibler has received grants from EMCREG-International, Millennium, Schering-Plough, sanofi-aventis, and Bristol-Myers Squibb. Dr Ohman serves as a consultant for Abiomed, Datascope, Inovise, Liposcience, Response Biomedical, and The Medicines Company; is a principal investigator for Bristol-Myers Squibb, Eli Lilly, Millennium, sanofi-aventis, Schering-Plough, Daiichi Sankyo, and The Medicines Company; is a member of the speakers bureau for CV Therapeutics and The Medicines Company; and is a stockholder in Inovise. Dr Roe serves as an investigator for Daiichi-Sankyo, Eli Lilly, Portola Pharmaceuticals, KAI Pharmaceuticals, Schering-Plough, and sanofi-aventis and is a consultant for KAI Pharmaceuticals and Schering-Plough; he is also a Clinical Event Committee Reviewer for Genentech and Novartis and is a member of the speakers bureau for Schering-Plough. Dr Pollack serves as a speaker for Schering-Plough and sanofi-aventis; receives research support from sanofi-aventis and GlaxoSmithKline; and serves as a consultant to Schering-Plough, BMS, sanofi-aventis, and The Medicines Company. Dr Peterson has received research grants from Bristol-Myers Squibb/Sanofi Pharmaceuticals Partner- Figure 5 . In-hospital mortality among patients having a major bleed vs those without a major bleed across CRUSADE bleeding score quintiles in the derivation cohort. Within each risk quintile, the P value for difference between patients who had a bleed vs those who did not was Ͻ0.0001 ( 2 adjusted for hospital clustering).
